The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study
The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.
• Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation
• Routine administration of proton pump inhibitors for 6 months postoperatively
• No intake of proton pump inhibitors at least 4 weeks prior to study investigation
• No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule
• No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation)
• Informed consent as documented by signature